Aktie A407UV AGEX THERAPEUTICS, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen AgeX Therapeutics, Inc.

Aktien

A407UV

US00848H2076

AGE

Verzögert Nyse
Andere Börsenplätze
 21:10:00 26.03.2024 		% 5 Tage % 1. Jan.
11.1 USD -11.90% Intraday Chart für AgeX Therapeutics, Inc. -16.48% -18.02%
26.03. Serina Therapeutics, Inc. hat die Übernahme von AgeX Therapeutics, Inc. (NYSEAM:AGE) von einer Gruppe von Aktionären in einer Reverse-Merger-Transaktion abgeschlossen. CI
22.03. AgeX Therapeutics, Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Serina Therapeutics, Inc. completed the acquisition of AgeX Therapeutics, Inc. from a group of shareholders in a reverse merger transaction.
AgeX Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
AgeX Therapeutics Reports Fourth Quarter and Annual 2023 Financial Results
AGEX THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AgeX Therapeutics, Inc. - AGE
AgeX Therapeutics, Inc. Appoints Steven Mintz as a Director, Member of Audit Committee, Compensation Committee and Nominating & Corporate Governance Committee
AgeX Therapeutics : New Financial Obligation - Form 8-K
AgeX Therapeutics : Termination of Material Agreement - Form 8-K
Agex Therapeutics, Inc. Terminates Nafees Malik as Chief Operating Officer, Effective on December 27, 2023
Pfizer Signs License Agreement With Serina Therapeutics to Gain Access to POZ Polymer Technology
Earnings Flash (AGE) AGEX THERAPEUTICS Posts Q3 Revenue $67,000
AgeX Therapeutics Reports Third Quarter 2023 Financial Results
AgeX Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
AgeX Therapeutics : New Financial Obligation - Form 8-K
AgeX Therapeutics, Inc. Announces Departure of Dr. Michael H. May as Director of the Company
AGEX THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AgeX Therapeutics, Inc. - AGE
AGE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of AgeX Therapeutics, Inc. Is Fair to Shareholders
Serina Therapeutics and AgeX Therapeutics Enter into Merger Agreement
Serina Therapeutics, Inc. entered into a merger agreement to acquire AgeX Therapeutics, Inc. from shareholders in a reverse merger transaction.
AgeX Therapeutics : New Financial Obligation - Form 8-K
Earnings Flash (AGE) AGEX THERAPEUTICS Posts Q2 Revenue $9,000
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A407UV Aktie
  4. Nachrichten AgeX Therapeutics, Inc.
  5. Andere Sprachen